title: Patients with known or suspected lung cancer: evaluation of clinical management changes due to 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) study.
abstract: OBJECTIVE
  To determine prospectively from the referring physician's point of view the impact of F-fluorodeoxyglucose positron emission tomography (F-FDG PET) results on the management decisions in patients with known or suspected lung cancer.
  
  
  METHODS
  Seventy-five consecutive patients (58 men, 17 women; age range, 33-82 years; mean age, 64 years) with a diagnosis of a pulmonary lesion, obtained by means of morphological imaging studies and/or cytological sampling, were included in the study. The patient population consisted of three groups: (A) patients (n=18) with a solitary lung nodule; (B) patients (n=37) with untreated lung cancer; and (C) patients (n=20) with treated lung cancer. All were referred for whole-body F-FDG PET within 15 days (mean, 11 days) of lung lesion detection. To determine whether and how PET findings could modify the treatment strategy, a questionnaire was sent to the referring physician before and after the PET results. With regard to the treatment strategy, four major options were recognized: (1) further diagnostic investigations; (2) medical therapy; (3) surgical treatment; (4) wait-and-see. For data analysis, intermodality changes, defined as changes between treatment strategies related to PET findings, were considered.
  
  
  RESULTS
  Before the PET study, the planned management for the overall patient population was as follows: further diagnostic investigations in 44 cases (58%), medical therapy in 17 (23%), surgical treatment in nine (12%) and wait-and-see in five (7%). After the PET study, further diagnostic tools were indicated in 27 cases (36%), medical therapy in 17 (23%), surgical treatment in 28 (37%) and wait-and-see in three (4%). Relative to the initially planned strategy, changes in patient management after PET imaging occurred in 34 (45%) cases. Overall, the most relevant variation after PET concerned the surgical treatment strategy. The highest percentage (67%) of changes in management after PET was found in patients with a solitary pulmonary nodule; the percentages of changes of the three patient groups were significantly different (chi-squared test; P=0.021).
  
  
  CONCLUSIONS
  In patients with known or suspected lung cancer, F-FDG PET results determined significant variations in major clinical management decisions.
authors.affiliation: Division of Nuclear Medicine, Institute H. S. Raffaele, University of Milan, Via Olgettina 60, 20132 Milan, Italy.
authors.forename: Gino
authors.initials: G
authors.lastname: Pepe
authors.forename: Claudio
authors.initials: C
authors.lastname: Rossetti
authors.forename: Sandro
authors.initials: S
authors.lastname: Sironi
authors.forename: Claudio
authors.initials: C
authors.lastname: Landoni
authors.forename: Luigi
authors.initials: L
authors.lastname: Gianolli
authors.forename: Ugo
authors.initials: U
authors.lastname: Pastorino
authors.forename: Piero
authors.initials: P
authors.lastname: Zannini
authors.forename: Maurizio
authors.initials: M
authors.lastname: Mezzetti
authors.forename: Adelmo
authors.initials: A
authors.lastname: Grimaldi
authors.forename: Laura
authors.initials: L
authors.lastname: Galli
authors.forename: Cristina
authors.initials: C
authors.lastname: Messa
authors.forename: Ferruccio
authors.initials: F
authors.lastname: Fazio
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003657:Decision Making; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D007558:Italy / Q000453:epidemiology; D008175:Lung Neoplasms / Q000000981:diagnostic imaging* / Q000453:epidemiology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D049268:Positron-Emission Tomography / Q000379:methods / Q000706:statistics & numerical data*; D010818:Practice Patterns, Physicians'; D011379:Prognosis; D019275:Radiopharmaceuticals; D018570:Risk Assessment / Q000379:methods*; D012307:Risk Factors
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18